Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
OFIX's Cash-to-Debt is ranked higher than
97% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. OFIX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OFIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 1.31 Max: No Debt
Current: No Debt
Equity-to-Asset 0.73
OFIX's Equity-to-Asset is ranked higher than
67% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. OFIX: 0.73 )
Ranked among companies with meaningful Equity-to-Asset only.
OFIX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.67 Max: 0.85
Current: 0.73
0.36
0.85
Interest Coverage 47.83
OFIX's Interest Coverage is ranked lower than
55% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 97.42 vs. OFIX: 47.83 )
Ranked among companies with meaningful Interest Coverage only.
OFIX' s Interest Coverage Range Over the Past 10 Years
Min: 0.68  Med: 3.2 Max: 47.83
Current: 47.83
0.68
47.83
Piotroski F-Score: 8
Altman Z-Score: 5.74
WACC vs ROIC
5.90%
4.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 5.21
OFIX's Operating Margin % is ranked higher than
58% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. OFIX: 5.21 )
Ranked among companies with meaningful Operating Margin % only.
OFIX' s Operating Margin % Range Over the Past 10 Years
Min: -49.44  Med: 3.34 Max: 17.01
Current: 5.21
-49.44
17.01
Net Margin % 2.41
OFIX's Net Margin % is ranked higher than
52% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. OFIX: 2.41 )
Ranked among companies with meaningful Net Margin % only.
OFIX' s Net Margin % Range Over the Past 10 Years
Min: -43.98  Med: -1.32 Max: 9.73
Current: 2.41
-43.98
9.73
ROE % 3.50
OFIX's ROE % is ranked higher than
55% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. OFIX: 3.50 )
Ranked among companies with meaningful ROE % only.
OFIX' s ROE % Range Over the Past 10 Years
Min: -71.87  Med: -1.4 Max: 16.37
Current: 3.5
-71.87
16.37
ROA % 2.56
OFIX's ROA % is ranked higher than
60% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 0.07 vs. OFIX: 2.56 )
Ranked among companies with meaningful ROA % only.
OFIX' s ROA % Range Over the Past 10 Years
Min: -31.59  Med: -0.88 Max: 7.45
Current: 2.56
-31.59
7.45
ROC (Joel Greenblatt) % 16.99
OFIX's ROC (Joel Greenblatt) % is ranked higher than
67% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. OFIX: 16.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OFIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -121.91  Med: 9.79 Max: 27.87
Current: 16.99
-121.91
27.87
3-Year Revenue Growth Rate -2.40
OFIX's 3-Year Revenue Growth Rate is ranked lower than
69% of the 224 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. OFIX: -2.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OFIX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.5  Med: 12.1 Max: 17.7
Current: -2.4
-10.5
17.7
3-Year EBITDA Growth Rate -31.20
OFIX's 3-Year EBITDA Growth Rate is ranked lower than
90% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. OFIX: -31.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OFIX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -49.8  Med: 9.9 Max: 63.2
Current: -31.2
-49.8
63.2
GuruFocus has detected 1 Warning Sign with Orthofix International NV $OFIX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OFIX's 10-Y Financials

Financials (Next Earnings Date: 2017-02-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

OFIX Guru Trades in Q1 2016

Jim Simons 456,379 sh (+78.72%)
Paul Tudor Jones 22,708 sh (+64.59%)
Diamond Hill Capital 1,014,826 sh (+17.75%)
Mario Gabelli 99,125 sh (+0.30%)
Chuck Royce 73,200 sh (-23.59%)
Arnold Schneider 21,065 sh (-43.35%)
» More
Q2 2016

OFIX Guru Trades in Q2 2016

Jim Simons 570,179 sh (+24.94%)
Diamond Hill Capital 1,068,717 sh (+5.31%)
Chuck Royce 73,200 sh (unchged)
Arnold Schneider Sold Out
Mario Gabelli 96,325 sh (-2.82%)
Paul Tudor Jones 18,595 sh (-18.11%)
» More
Q3 2016

OFIX Guru Trades in Q3 2016

Diamond Hill Capital 1,176,748 sh (+10.11%)
Mario Gabelli 96,725 sh (+0.42%)
Jim Simons 524,200 sh (-8.06%)
Chuck Royce 55,700 sh (-23.91%)
Paul Tudor Jones 13,279 sh (-28.59%)
» More
Q4 2016

OFIX Guru Trades in Q4 2016

Paul Tudor Jones 29,923 sh (+125.34%)
Jim Simons 745,579 sh (+42.23%)
Chuck Royce 55,700 sh (unchged)
Mario Gabelli 95,425 sh (-1.34%)
Diamond Hill Capital 997,215 sh (-15.26%)
» More
» Details

Insider Trades

Latest Guru Trades with OFIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113 
Compare:NYSE:CRY, NAS:GNMK, NAS:KTWO, NAS:ARAY, OTCPK:MZRTF, NAS:MDXG, NYSE:IVC, NAS:CSII, NAS:XENT, NAS:AXGN, NAS:EXAC, NAS:VASC, NAS:ELOS, OTCPK:NMRD, NAS:CUTR, NAS:TCMD, NAS:VRAY, OTCPK:IPDQF, NYSE:ITGR, NAS:RTIX » details
Traded in other countries:OFX.Germany,
Orthofix International NV is a diversified medical device company. The Company is engaged in developing and delivering repair & regenerative solutions to the spine and orthopedic markets.

Orthofix International NV was formed on October 19, 1987 under the laws of the Netherlands Antilles. The Company is a diversified, medical device company engaged in developing and delivering repair and regenerative solutions to the spine and orthopedic markets. Its products are designed to address the lifelong bone-and-joint health needs of patients of all ages, helping them achieve a more active and mobile lifestyle. The Company designs, develops, manufactures, markets and distributes medical devices used mainly by musculoskeletal medical specialists for spine and orthopedic applications. Its main products are spinal implant products human cellular and tissue based products ('HCT/P products') used in surgical procedures, non-invasive regenerative stimulation products used to enhance bone growth and the success rate of spinal fusions and to treat non-union fractures, and external and internal fixation devices used in fracture repair, limb lengthening and bone reconstruction. The Company has administrative and training facilities in the United States, Brazil, the United Kingdom, France, Germany, Puerto Rico and Italy and manufacturing facilities in the U.S. and Italy. The Company directly distributes its products in the U.S., the United Kingdom, Italy, Germany, France, Belgium, Brazil, Australia, and Puerto Rico. The Company manages its business by its four strategic business units (SBUs), which are comprised of BioStim, Biologics, Extremity Fixation, Spine Fixation. The BioStim SBU manufactures, distributes, and provides support services for a portfolio of devices for enhancing bone fusion that utilize the Company's patented pulsed electromagnetic (PEMF) technology. These Food and Drug Administration-approved Class 3 medical devices are indicated as an adjunctive treatment to enhance fusion success in cervical and lumbar spine fusion as well as a therapeutic treatment for non-healing fractures outside of the spine. The Biologics SBU provides a portfolio of regenerative products that allow physicians to successfully treat various spinal and orthopedic conditions. This SBU specializes in the marketing of the Company's regeneration tissue forms. Biologics distributes its tissues through a network of distributors, sales, representatives and affiliates to market to hospitals, doctors, and other healthcare providers, mainly in the U.S. The Company's partnership with MTF allows it to exclusively market its Trinity Evolution and Trinity Elitetissue forms for musculoskeletal defects to enhance bone fusion. The Extremity Fixation SBU offers products that allow physicians to successfully treat various orthopedic conditions unrelated to the spine. This SBU specializes in the design, development, and marketing of the Company's orthopedic products used in fracture repair, deformity correction and bone reconstruction. Extremity Fixation distributes its products through a network of distributors, sales representatives, and affiliates. The Spine

Ratios

vs
industry
vs
history
PE Ratio 72.24
OFIX's PE Ratio is ranked lower than
82% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.50 vs. OFIX: 72.24 )
Ranked among companies with meaningful PE Ratio only.
OFIX' s PE Ratio Range Over the Past 10 Years
Min: 8.14  Med: 27.36 Max: 394.17
Current: 72.24
8.14
394.17
Forward PE Ratio 21.69
OFIX's Forward PE Ratio is ranked higher than
59% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 23.92 vs. OFIX: 21.69 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 64.73
OFIX's PE Ratio without NRI is ranked lower than
80% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 25.48 vs. OFIX: 64.73 )
Ranked among companies with meaningful PE Ratio without NRI only.
OFIX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.14  Med: 25.44 Max: 93.47
Current: 64.73
8.14
93.47
PB Ratio 2.45
OFIX's PB Ratio is ranked higher than
59% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. OFIX: 2.45 )
Ranked among companies with meaningful PB Ratio only.
OFIX' s PB Ratio Range Over the Past 10 Years
Min: 0.77  Med: 2.02 Max: 3.32
Current: 2.45
0.77
3.32
PS Ratio 1.72
OFIX's PS Ratio is ranked higher than
68% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 3.29 vs. OFIX: 1.72 )
Ranked among companies with meaningful PS Ratio only.
OFIX' s PS Ratio Range Over the Past 10 Years
Min: 0.31  Med: 1.56 Max: 2.32
Current: 1.72
0.31
2.32
Price-to-Free-Cash-Flow 20.28
OFIX's Price-to-Free-Cash-Flow is ranked higher than
64% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. OFIX: 20.28 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
OFIX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.18  Med: 19.67 Max: 572.14
Current: 20.28
7.18
572.14
Price-to-Operating-Cash-Flow 12.57
OFIX's Price-to-Operating-Cash-Flow is ranked higher than
73% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 18.12 vs. OFIX: 12.57 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
OFIX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.77  Med: 12.37 Max: 267.95
Current: 12.57
5.77
267.95
EV-to-EBIT 29.46
OFIX's EV-to-EBIT is ranked lower than
62% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.48 vs. OFIX: 29.46 )
Ranked among companies with meaningful EV-to-EBIT only.
OFIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -38  Med: 18.6 Max: 272.1
Current: 29.46
-38
272.1
EV-to-EBITDA 29.46
OFIX's EV-to-EBITDA is ranked lower than
76% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 15.79 vs. OFIX: 29.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
OFIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -144.1  Med: 12.6 Max: 769.5
Current: 29.46
-144.1
769.5
Current Ratio 2.22
OFIX's Current Ratio is ranked lower than
55% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. OFIX: 2.22 )
Ranked among companies with meaningful Current Ratio only.
OFIX' s Current Ratio Range Over the Past 10 Years
Min: 1.56  Med: 3.4 Max: 5.24
Current: 2.22
1.56
5.24
Quick Ratio 1.44
OFIX's Quick Ratio is ranked lower than
60% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. OFIX: 1.44 )
Ranked among companies with meaningful Quick Ratio only.
OFIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 2.57 Max: 3.82
Current: 1.44
1.13
3.82
Days Inventory 256.07
OFIX's Days Inventory is ranked lower than
79% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 130.88 vs. OFIX: 256.07 )
Ranked among companies with meaningful Days Inventory only.
OFIX' s Days Inventory Range Over the Past 10 Years
Min: 201.26  Med: 244.73 Max: 336.86
Current: 256.07
201.26
336.86
Days Sales Outstanding 47.57
OFIX's Days Sales Outstanding is ranked higher than
78% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 66.78 vs. OFIX: 47.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
OFIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.57  Med: 82.39 Max: 105.88
Current: 47.57
47.57
105.88
Days Payable 61.05
OFIX's Days Payable is ranked higher than
51% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. OFIX: 61.05 )
Ranked among companies with meaningful Days Payable only.
OFIX' s Days Payable Range Over the Past 10 Years
Min: 48.79  Med: 69.53 Max: 101.56
Current: 61.05
48.79
101.56

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.20
OFIX's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. OFIX: 1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OFIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.1  Med: -1.5 Max: 1.2
Current: 1.2
-7.1
1.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 8.22
OFIX's Price-to-Net-Current-Asset-Value is ranked lower than
57% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 6.59 vs. OFIX: 8.22 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OFIX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.2  Med: 5.24 Max: 235
Current: 8.22
2.2
235
Price-to-Tangible-Book 3.20
OFIX's Price-to-Tangible-Book is ranked higher than
59% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 4.24 vs. OFIX: 3.20 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OFIX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.48  Med: 4.36 Max: 110.32
Current: 3.2
1.48
110.32
Price-to-Intrinsic-Value-Projected-FCF 1.61
OFIX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
68% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. OFIX: 1.61 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
OFIX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.32 Max: 2.51
Current: 1.61
0.55
2.51
Price-to-Median-PS-Value 1.10
OFIX's Price-to-Median-PS-Value is ranked lower than
60% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 0.99 vs. OFIX: 1.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OFIX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 1.17 Max: 2.3
Current: 1.1
0.32
2.3
Price-to-Graham-Number 3.04
OFIX's Price-to-Graham-Number is ranked lower than
66% of the 139 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. OFIX: 3.04 )
Ranked among companies with meaningful Price-to-Graham-Number only.
OFIX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.88  Med: 2.02 Max: 11.95
Current: 3.04
0.88
11.95
Earnings Yield (Greenblatt) % 3.37
OFIX's Earnings Yield (Greenblatt) % is ranked higher than
69% of the 337 Companies
in the Global Medical Devices industry.

( Industry Median: -0.30 vs. OFIX: 3.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OFIX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 3.5 Max: 17.4
Current: 3.37
0.4
17.4
Forward Rate of Return (Yacktman) % 3.60
OFIX's Forward Rate of Return (Yacktman) % is ranked lower than
63% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 8.88 vs. OFIX: 3.60 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
OFIX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -41.7  Med: 3.8 Max: 32.7
Current: 3.6
-41.7
32.7

More Statistics

Revenue (TTM) (Mil) $405.9
EPS (TTM) $ 0.52
Beta0.46
Short Percentage of Float5.58%
52-Week Range $32.51 - 48.25
Shares Outstanding (Mil)17.83

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 409 413 424 435
EPS ($) 1.43 1.70 1.84 1.85
EPS without NRI ($) 1.43 1.70 1.84 1.85
EPS Growth Rate
(Future 3Y To 5Y Estimate)
14.30%
Dividends per Share ($)
» More Articles for OFIX

Headlines

Articles On GuruFocus.com
Three Growing Companies Worth a Second Look Oct 09 2013 
Weekly CEO Buys Highlight: MOSY, PMT, APA, CUBI, OFIX May 26 2013 
Weekly 3-Year Low Highlights: SBY, PER, OFIX, EDG May 14 2013 
Orthofix International N.V. Reports Operating Results (10-K) Mar 03 2011 
Orthofix International N.V. (OFIX) CEO Alan Milinazzo buys 1,100 Shares Nov 09 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Oct 28 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Jul 29 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Apr 29 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Nov 06 2009 
Orthofix International N.V. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
Orthofix International Schedules Fourth Quarter 2016 and Fiscal Year 2016 Earnings Release and... Feb 16 2017
Orthofix Settles Bribery, Accounting Probes Jan 18 2017
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 18 2017
SEC fines Orthofix International $14 million for accounting failures, foreign bribery Jan 18 2017
Orthofix Announces Resolution of SEC Investigations Jan 18 2017
Orthofix to pay $14 mln to settle charges it paid off doctors -U.S. SEC Jan 18 2017
Orthofix International NV – Value Analysis (NASDAQ:OFIX) : January 11, 2017 Jan 11 2017
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 10 2017
Orthofix Announces Preliminary 2016 Fourth Quarter and Full Year Net Sales Results Jan 10 2017
Orthofix International NV breached its 50 day moving average in a Bullish Manner : OFIX-US : January... Jan 10 2017
OFIC NOTICE: Rosen Law Firm Announces Investigation of Securities Claims Against Orthofix... Jan 09 2017
Orthofix Receives FDA and CE Mark Approvals for New Bone Growth Stimulators Jan 09 2017
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Orthofix International N.V.... Dec 21 2016
Federman & Sherwood Investigates Orthofix International N.V. for Possible Violations of Federal... Dec 21 2016
Orthofix to Present at J.P. Morgan Healthcare Conference Dec 20 2016
ORTHOFIX INTERNATIONAL INVESTOR ALERT: Hagens Berman Alerts Orthofix International Investors to... Dec 19 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations... Dec 16 2016
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Orthofix... Dec 16 2016
INVESTOR LOSS ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Orthofix... Dec 16 2016
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Change in Directors or Principal Officers, Regulation... Dec 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)